From 2018 to 2022, the overall death rate for lung and bronchus cancer in the Kentucky was 61 per 100,000 for males and 43.2 per 100,000 for females. This statistic presents the death rates for lung and bronchus cancer in the United States from 2018 to 2022, by state and gender.

In the period between 2018 and 2022, there were approximately 179 cancer deaths per 100,000 white males in the United States. This statistic shows cancer death rates in the United States for the period 2018-2022, by ethnic group and gender.

One-year and five-year net survival for adults (15-99) in England diagnosed with one of 29 common cancers, by age and sex.

This statistic shows the share of total survivals from childhood cancer in Sweden in 2018, by type. The highest share of children who survived childhood cancer were children with leukemia. Children ill with leukemia composed 30 percent of the total childhood cancer survival in Sweden in 2018.

It was estimated that in 2018 there were 20 cervical cancer deaths per 100,000 women in Southern Africa. Most cervical cancer cases are due to human papillomavirus (HPV), which is the most common sexually transmitted infection worldwide.

In the period 2018 to 2022, a total of approximately 173 men per 100,000 inhabitants died of cancers of all kinds in the United States, compared to an overall cancer death rate of 126 per 100,000 population among women. This statistic shows cancer death rates in the U.S. for the period from 2018 to 2022, by type and gender.

ObjectivesWhile timely assessment of long-term survival for patients with cervical cancer is essential for the evaluation of early detection and screening programs for cervical cancer, those data are extremely scarce in China. We aimed to timely and accurately assess long-term survival for patients with cervical cancer in eastern China, using cancer registry data from Taizhou, eastern China.MethodsPatients diagnosed with cervical cancer during 2004–2018 from four cancer registries with high-quality data from Taizhou, eastern China were included. A period analysis was used to calculate the 5-year relative survival (RS) overall and on stratification by sex, age at diagnosis, and region. Additionally, the projected 5-year relative survival (RS) of patients with cervical cancer during 2019–2023 was evaluated, using a model-based period analysis.ResultsOverall 5-year RS for patients with cervical cancer during 2014–2018 reached 90.9%. When stratified by age at diagnosis, we found a clear age gradient for 5-year RS, declining from 95.6% for age 74 years, while urban areas had higher 5-year RS compared to rural areas (92.9 vs. 88.6%). We found a clear increasing trend of 5-year RS during 2004–2018 overall and on stratification by region and age at diagnosis. The projected overall 5-year RS is expected to reach 94.2% for the period 2019–2023.ConclusionsWe found that, for the first time in China, using period analysis, the most up-to-date (during 2014–2018) 5-year RS for patients with cervical cancer reached 90.9%. Our data have important implications for the timely evaluation of early detection and screening programs for patients with cervical cancer in eastern China.

Age-standardized incidence-based mortality rates, and annual percent changes in primary liver cancer rates, 1978–2018.

Trends in five-year relative survival for selected cancers by long-term summary stage, SEER-8, 1975-2018

Snapshot img

Cancer Registry Software Market Size 2024-2028

The cancer registry software market size is forecast to increase by USD 97.1 million at a CAGR of 12.75% between 2023 and 2028.

The growing prevalence of cancer cases is the key driver of the cancer registry software market. CDC is a key player, specializing in providing advanced cancer registry software solutions, including Registry Plus. These systems facilitate accurate and efficient data management for healthcare organizations, enabling effective tracking, analysis, and reporting of cancer patient information as well as supporting cancer immunotherapy and cancer diagnostics. By supporting improved patient care and research outcomes, CDC's solutions are essential in addressing the increasing demand for comprehensive cancer data management. 
Additionally, data privacy and security concerns are driving the market, as healthcare organizations prioritize protecting sensitive patient information. These trends are shaping the market, which is expected to continue its growth trajectory In the coming years.

What will be the Size of the Cancer Registry Software Market During the Forecast Period?

Request Free Sample

The market is experiencing significant growth due to the increasing incidence of cancer and the need for efficient and accurate data management In the healthcare industry. With the adoption of Electronic Health Records (EHRs) and the shift towards evidence-based medicine, cancer registry software solutions have become essential tools for medical professionals to track cancer treatment, therapeutics, and patient outcomes. 
These solutions enable the collection and analysis of data on cancer prevalence, diagnostics, and specific area-focused cancer incidence. They provide valuable insights into cancer-specific outcomes, including chemotherapy, surgery, supportive treatments, and post-endoscopic resection. Furthermore, regulatory guidance documents mandate the use of cancer registry software to ensure compliance with healthcare standards and reduce healthcare costs.
Medical professionals rely on these software solutions to improve patient care and support the ongoing research and development of new cancer treatments.

How is this Cancer Registry Software Industry segmented and which is the largest segment?

The cancer registry software industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Government and third party
  Pharma biotech and medical device companies
  Hospitals and medical practice
  Private payers
  Research institutes


Type

  Stand-alone software
  Integrated software


Deployment

  On-premise
  Cloud


Component

  Commercial
  Public


Geography

  North America

    Canada
    US


  Europe

    Germany
    Italy


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The government and third party segment is estimated to witness significant growth during the forecast period. Cancer registry software plays a pivotal role in managing data related to cancer cases for government hospitals and third-party agencies. This software facilitates the collection, management, and analysis of data on cancer incidence, prevalence, and mortality rates. This information is essential for public health planning, resource allocation, and policy development. By identifying trends and patterns, governments and agencies can target high-risk populations, address geographic disparities, and recognize emerging cancer types. Cancer registry software enhances the quality of cancer care by enabling the evaluation of treatment practices against clinical guidelines and benchmarking outcomes against standards. The software supports seamless data integration and interoperability with healthcare systems, ensuring coordinated care for cancer patients.

Medical professionals and patients alike benefit from improved cancer care through evidence-based medicine, cancer-specific outcomes, and research institutes. Software solutions cater to various cancer types, including lung cancer, and support cancer staging, treatment, disease management, diagnostics, chemo, surgery, and supportive therapies. These solutions integrate with electronic health records (EHR), enabling secure data storage and access to essential health information. Data security and security protocols are prioritized to protect patient privacy and prevent medical identity theft. Cancer registry software supports population health management, healthcare cost containment, and chronic disease management. It aligns with healthcare quality goals and streamlines hospital workflows, making it an essential tool for oncology departments, clinics, hospitals, medical practices, pharmaceutical, biotech, and medical de

It was estimated that in 2018 there were 2.4 oropharynx cancer deaths per 100,000 men in Eastern Europe, compared to just .2 deaths per 100,000 women. A large number of oropharynx cancer cases are due to human papillomavirus (HPV), which is the most common sexually transmitted infection worldwide.

Abstract copyright UK Data Service and data collection copyright owner.

The National Cancer Patient Experience Surveys (NCPES) began in 2010, after the 2007 'Cancer Reform Strategy' set out a commitment to establish a new survey programme. The NCPES is intended to be a vehicle enabling and supporting quality improvement in the NHS and has been used by national bodies, NHS Hospitals, specialist cancer teams, and national and condition specific charities to improve services for patients. It is designed to monitor national progress on cancer care and to help gather vital information on the Transforming Inpatient Care Programme, the National Cancer Survivorship Initiative and the National Cancer Equality Initiative. An Advisory Group was set up for the NCPES with the National Cancer Director, professionals, voluntary sector representatives, academics and patient survey experts. The Group agreed on the following guiding principles and objectives:

• a standard national survey tool was to be used
• surveys would be conducted at Trust level and identify cancer groups
• the survey would cover all cancers and include the whole care pathway
• the survey should use the word 'cancer' unlike the 2000 and 2004 surveys
• the survey focus would be on patients (rather than carers)
• the data would be used for benchmarking performance across Trusts and by cancer groups where numbers allow
• the data would be used to inform national and local policy
• the data would be made publicly available whilst observing patient data protection requirements and maintaining confidentiality.

The survey is intended to be a vehicle enabling and supporting quality improvement in the NHS and has been used by national bodies, NHS Hospitals, specialist cancer teams, and national and condition specific charities to improve services for patients.

The NCPES has been replicated in Wales (see SN 7510), Northern Ireland, the Isle of Man, parts of Australia, and the Middle East. Further information can be found on the Quality Health Limited National Cancer Patient Experience Survey webpage and the NHS England Cancer Patient Experience Survey webpage.

2010-2015 surveys temporarily withdrawn
The data for the 2010-2014 surveys were temporarily withdrawn at the request of the depositor in October 2015. The 2015 data (SN 8163 and the Special Licence version, SN 8164) were temporarily withdrawn at the request of the depositor in February 2020.

The purposes of the Cancer Patient Experience Survey, 2018 are: to secure continuous improvement by building on the results of previous surveys, enabling local providers and Cancer Alliances to assess their performance improvement with other providers; to enable commissioners to assess local improvements in cancer patient experience; to provide NHS England and NHS Improvement with an up to date overview of cancer patient experience across England; to provide NHS England and NHS Improvement with data on each participating trust and the areas on which quality improvement needs to be focused; to enable patients to make informed choices about where to go for cancer treatment via publishing the provider level analysis on publicly available websites.

The data is based on the experience of an initial sample of 123,512 cancer patients, reduced to 115,067 through checking and deceased status measures, and in total 73,817 responded, either by post or online, phone or through the survey providers translation service. The response rate was 64% overall, in line with the levels attained in previous years. The CPES is intended to be a vehicle enabling and supporting quality improvement in the NHS and has been used by national bodies, NHS Hospitals, specialist cancer teams, and national and condition specific charities to improve services for patients

This study is an edited version of the data collection, subject to standard End User Licence access conditions. NHS England has devised a set of rules to be applied to the data and edited the dataset in order to suppress any personally identifiable information in accordance with the ICO's guidelines on anonymisation and the National Statistician's guidance on suppressing disclosive data. These rules are designed such that there will be no less than three respondents shown when any given cross-tabulation is applied to the data.

A more detailed version of the 2018 data, held under SN 8571, is available under restrictive Special Licence Access conditions. This contains hospital of treatment, geographic information and more detailed demographic information.

Main Topics:
The data cover different stages of the patients' 'cancer journey', from diagnosis to outpatient treatment:

• initial GP visits before diagnosis (how many appointments, time period)
• diagnostic tests (understanding of...

Directly age standardised mortality rate from breast cancer for females in the respective time period per 100,000 registered female patients. March 2020: In addition to the changes in March 2019, the indicator production process has been fully automated. As a result there are two changes to this publication: 1) Data in this file are published for 2016-2018 only; all data is based on the most recent methodology. For the historic time series of this indicator please refer to the zip files in the June 2018 publication: https://digital.nhs.uk/data-and-information/publications/clinical-indicators/ccg-outcomes-indicator-set/archive/ccg-outcomes-indicator-set---june-2018 Please note, neither version of the file contains data for 2015-2017; changes in the data processing meant the 2015 data was not comparable to the 2016 and 2017 data processed under the new method. 2) Data are run against CCGs which were in existence at the time of processing. As of the March 2019 release the processing of the Primary Care Mortality Database (PCMD) and the standard population used to calculate the indicator for new data periods changed; this file now contains only those data periods processed under the new method. For the historic time series of this indicator please refer to the June 2018 publication referenced above. Legacy unique identifier: P01819

Cervical cancer is a type of cancer that occurs in the cells of the cervix, which connects the vagina (birth canal) to the upper part of the uterus (Mayo Clinic, 2021). All women are at risk for cervical cancer. It occurs most often in women ages 30 years and older (Centers for Disease Control and Prevention, 2021). Long-lasting infection with certain types of human papillomavirus (HPV) is the main cause of cervical cancer. Almost all cervical cancer cases (99%) are linked to infection with HPV, an extremely common virus transmitted through sexual contact (World Health Organization, 2021). In 2018, an estimated 570,000 women were diagnosed with cervical cancer worldwide, and about 311,000 women died from the disease (World Health Organization, 2021).
In the 8MM, diagnosed incident cases of cervical cancer are expected to increase from 109,891cases in 2020 to 123,846 cases in 2030, at an Annual Growth Rate (AGR) of 1.27%. In 2030, urban China will have the highest number of diagnosed incident cases of cervical cancer in the 8MM, with 83,479 cases, whereas Spain will have the fewest diagnosed incident cases of cervical cancer with 2,147 cases. In the 8MM, the five-year diagnosed prevalent cases of cervical cancer are expected to increase from 394,378 cases in 2020 to 453,614 cases in 2030, at an AGR of 1.50%. GlobalData epidemiologists attribute the increase in the five-year diagnosed prevalent cases and diagnosed incident cases of cervical cancer to changes in the diagnosed incidence and survival rates, and population dynamics in each market. Read More

The National Cancer Patient Experience Surveys (NCPES) began in 2010, after the 2007 'Cancer Reform Strategy' set out a commitment to establish a new survey programme. The NCPES is intended to be a vehicle enabling and supporting quality improvement in the NHS and has been used by national bodies, NHS Hospitals, specialist cancer teams, and national and condition specific charities to improve services for patients. It is designed to monitor national progress on cancer care and to help gather vital information on the Transforming Inpatient Care Programme, the National Cancer Survivorship Initiative and the National Cancer Equality Initiative. An Advisory Group was set up for the NCPES with the National Cancer Director, professionals, voluntary sector representatives, academics and patient survey experts. The Group agreed on the following guiding principles and objectives:

• a standard national survey tool was to be used
• surveys would be conducted at Trust level and identify cancer groups
• the survey would cover all cancers and include the whole care pathway
• the survey should use the word 'cancer' unlike the 2000 and 2004 surveys
• the survey focus would be on patients (rather than carers)
• the data would be used for benchmarking performance across Trusts and by cancer groups where numbers allow
• the data would be used to inform national and local policy
• the data would be made publicly available whilst observing patient data protection requirements and maintaining confidentiality.

The survey is intended to be a vehicle enabling and supporting quality improvement in the NHS and has been used by national bodies, NHS Hospitals, specialist cancer teams, and national and condition-specific charities to improve services for patients.

The NCPES has been replicated in Wales (see SN 7510), Northern Ireland, the Isle of Man, parts of Australia, and the Middle East. Further information can be found on the NHS England Cancer Patient Experience Survey webpage.

2010-2014 data unavailable:
The 2010-2014 NCPES End User Licence data were temporarily withdrawn at the depositor's request in October 2015; only the 2015 survey (SN 8163) is currently available. In addition, there is no Special Licence version of the 2010-2014 data; 2015 is the first year in the series for which both versions are held.

The purposes of the National Cancer Patient Experience Survey, 2018: Special Licence are: to secure continuous improvement by building on the results of previous surveys, enabling local providers and Cancer Alliances to assess their performance improvement with other providers; to enable commissioners to assess local improvements in cancer patient experience; to provide NHS England and NHS Improvement with an up to date overview of cancer patient experience across England; to provide NHS England and NHS Improvement with data on each participating trust and the areas on which quality improvement needs to be focused; to enable patients to make informed choices about where to go for cancer treatment via publishing the provider level analysis on publicly available websites.

The data is based on the experience of an initial sample of 123,512 cancer patients, reduced to 115,067 through checking and deceased status measures, and in total 73,817 responded, either by post or online, phone or through the survey providers translation service. The response rate was 64% overall, in line with the levels attained in previous years. The CPES is intended to be a vehicle enabling and supporting quality improvement in the NHS and has been used by national bodies, NHS Hospitals, specialist cancer teams, and national and condition specific charities to improve services for patients

This study is subject to restrictive Special Licence Access conditions because it contains detailed data on the treatment and experiences of cancer patients. A less detailed version of the data, held under SN 8570, is available under standard End User Licence access conditions; it contains no geographic information and less detailed demographic information. Users are advised to check SN 8570 first to see whether it is sufficient for their research requirements before considering making a Special Licence Access application for this study.

This statistic shows the lung cancer survival rate among men and women in Argentina between 2012 and 2018, broken down by years since diagnostic. The data shows that Argentinian women had a probability of almost 52 percent to survive to a lung cancer after one year since the diagnostic. This probability decreases to 44.8 percent for men.

Azerbaijan Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 27.200 % in 2019. This records a decrease from the previous number of 27.400 % for 2018. Azerbaijan Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 30.050 % from Dec 2000 (Median) to 2019, with 20 observations. The data reached an all-time high of 32.500 % in 2000 and a record low of 27.200 % in 2019. Azerbaijan Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Azerbaijan – Table AZ.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].

Market Overview:

Middle East cancer diagnostics market size is projected to exhibit a growth rate (CAGR) of 7.65% during 2024-2032. The growing prevalence of cancer among the masses, rising construction of various hospitals and cancer research centers to provide quality healthcare services to patients, and increasing integration of cutting-edge technologies represent some of the key factors driving the market.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2032
Historical Years	2018-2023
Market Growth Rate (2024-2032)	7.65%

Cancer diagnostics refers to the methods and tools used to detect, classify, and monitor cancer. It involves analyzing biological samples or imaging studies to identify abnormal cells or tumors. It employs various imaging modalities, including X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, to visualize tumors and assess their size, location, and involvement with surrounding tissues. It involves the removal and examination of a small tissue sample to determine if cancer cells are present. It consists of blood tests, such as tumor markers and complete blood count (CBC), providing valuable information about the presence of cancer cells, the response of the body to cancer, and overall health. It employs various molecular techniques, including next-generation sequencing (NGS), polymerase chain reaction (PCR), and deoxyribonucleic acid (DNA) sequencing, to analyze the genetic and molecular characteristics of cancer cells and assist in identifying specific mutations and guiding targeted therapies. It allows for timely intervention, increasing the chances of successful treatment and improved survival rates. Cancer diagnostics contribute to the era of precision medicine by identifying specific molecular and genetic characteristics of tumors, enabling targeted therapies tailored to individual patients. It also helps in reducing unnecessary treatments and minimizing side effects, thereby enhancing the overall quality of life for cancer patients.

Middle East Cancer Diagnostics Market Trends:

At present, the increasing prevalence of cancer among the masses due to the adoption of unhealthy lifestyles and excessive consumption of alcohol represents one of the crucial factors impelling the growth of the market in the Middle East. Besides this, the rising integration of cutting-edge technologies, such as next-generation sequencing (NGS), liquid biopsy, and artificial intelligence (AI), which enable the comprehensive analysis of genomic alterations, allowing for a more precise and personalized approach to cancer diagnosis and treatment is contributing to the market growth in the region. In addition, the growing demand for non-invasive methods for detecting circulating tumor DNA, ribonucleic acid (RNA), and proteins in the blood, providing valuable insights into tumor dynamics and facilitating early cancer detection, is offering a favorable market outlook. Apart from this, governing agencies and healthcare organizations in the region are increasingly investing in screening initiatives to detect cancer at its earliest stages when treatment options are more effective. This emphasis on early detection improves survival rates and reduces the overall cost of cancer treatment by minimizing the need for extensive and costly interventions at later stages of the disease. Additionally, molecular diagnostic techniques, such as fluorescence in situ hybridization (FISH), enable the identification of specific genetic and molecular markers associated with various cancers. This molecular-level precision allows for more accurate diagnosis, prognosis, and treatment selection. Moreover, the increasing construction of various hospitals and cancer research centers to provide quality healthcare services to patients is bolstering the market growth in the region.

Middle East Cancer Diagnostics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the regional and country levels for 2024-2032. Our report has categorized the market based on product, technology, application, and end user.

Product Insights:

https://www.imarcgroup.com/CKEditor/a38f8d72-d7ab-486a-9117-ac1854638614other-regions1.webp" style="height:450px; width:800px" />

• Consumables
  • Antibodies
  • Kits and Reagents
  • Probes
  • Others
• Instruments
  • Pathology-Based Instruments
  • Imaging Instruments
  • Biopsy Instruments
    

The report has provided a detailed breakup and analysis of the market based on the product. This includes consumables (antibodies, kits and reagents, probes, and others) and instruments (pathology-based instruments, imaging instruments, and biopsy instruments).

Technology Insights:

• IVD Testing
  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Next-Generation Sequencing (NGS)
  • Microarrays
  • Flow Cytometry
  • Immunoassays
  • Others
• Imaging
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Ultrasound
• Biopsy Technique
  

A detailed breakup and analysis of the market based on the technology have also been provided in the report. This includes IVD testing (polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next-generation sequencing (NGS), microarrays, flow cytometry, immunoassays, and others), imaging (magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, and ultrasound), and biopsy technique.

Application Insights:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Others
  

The report has provided a detailed breakup and analysis of the market based on the application. This includes breast cancer, lung cancer, colorectal cancer, melanoma, and others.

End User Insights:

• Hospitals and Clinics
• Diagnostic Laboratories
• Others
  

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and clinics, diagnostic laboratories, and others.

Country Insights:

https://www.imarcgroup.com/CKEditor/4d06c107-0a8c-472f-ae85-bba61c1f53e2other-regions22.webp" style="height:450px; width:800px" />

• Saudi Arabia
• Turkey
• Israel
• United Arab Emirates
• Iran
• Iraq
• Qatar
• Kuwait
• Oman
• Jordan
• Bahrain
<li